Continue as a Guest

Sorry, there was a problem.

An unexpected error occurred and your request couldn't be handled. Please call a Dignity Health representative at
(844) 274-8497
OR
Chat with us here.

Reference code:
Continue as a Guest

Clinical Research


Dignity Health Cancer Institute of Greater Sacramento believes in the benefits of clinical research and its ability to elevate the level of care for all.

Cancer Research At Dignity Health Cancer Institute Of Greater Sacramento

In addition to giving patients access to the latest treatment options, our physicians develop expertise in decisions and outcome data. A particular technology may eliminate the need for more drastic surgeries, changing the standard of care. This is the value of a comprehensive research program and why it is an important part of the medical services we provide.

Breast Cancer

SWOG S1207

This is a Phase III, multicenter, randomized, placebo-controlled, double-blind study evaluating the use of 54 weeks of everolimus in addition to endocrine therapy.  Eligible patients would have been diagnosed with HER2 negative, hormone receptor (ER or PR) positive breast cancer and would have completed surgery, chemotherapy and radiation, if indicated.  Patients would be randomized to 54 weeks of either everolimus or placebo, supplied by the study, in addition to the endocrine therapy prescribed by their physician.  This study hopes to show that adding everolimus prior to recurrence can help prevent or delay the breast cancer from coming back.

Sponsor: NRG Oncology

Principal Investigator: Sonia Reichert, MD

Dr Reichert

Clinical Trials Website: ClinicalTrials.Gov

ABC Study

This is a Phase III, multicenter, randomized, placebo-controlled, double-blind study looking at the use of aspirin in patients with HER2 negative breast cancer.  Patient who have node positive breast cancer and who have completed their surgery, chemotherapy and radiation, if indicated, would be eligible to participate in the study.  Patients would be randomized to 5 years of aspirin or placebo, supplied by the study.  The study hopes to show that women taking aspirin after treatment for their breast cancer have a lower rate of recurrence than those who do not.

Sponsor: NRG Oncology

Principal Investigator:  Sonia Reichert, MD

Dr Reichert

Clinical Trials Website: ClinicalTrials.Gov

NRG-BR003

This is a Phase III, multicenter, randomized study looking at adding another type of chemotherapy to the standard treatment given to women with triple negative breast cancer.  Eligible patients will be newly diagnosed with TNBC (estrogen receptor negative, progesterone receptor negative and HER2 negative) and will have completed surgery.  The standard treatment for these patient is doxorubicin plus cyclophosphamide followed by paclitaxel.  In this study women will be randomized to receive this treatment or to have carboplatin added during the weekly paclitaxel treatments.  The goal of the study is to determine if adding carboplatin can reduce the chance of recurrence in patients with this type of breast cancer.

Sponsor: NRG Oncology

Principal Investigator: Sonia Reichert, MD

Dr Reichert

Clinical Trials Website: ClinicalTrials.Gov


Gynecologic Cancer

NRG-GY004

GY004 is a Phase III, multicenter, randomized study comparing  the effects of olaparib (a PARP-inhibitor), olaparib plus cediranib (a VEGF-inhibitor) and standard of care chemotherapy.  Eligible patient will have been diagnosed with ovarian, fallopian tube or primary peritoneal cancer that has returned after previous treatment with a platinum containing chemotherapy regimen.  Patients will be randomized to receive one of the three treatment options.  This study is not blinded.  Both olaparib and cediranib are oral medications.  The study hopes to show that either olaparib alone or in combination with cediranib is more effective at fighting this type of cancer than chemotherapy.

Sponsor: NRG Oncology

Principal Investigator: Delphine Ong, MD

Dr Ong

Clinical Trials Website: ClinicalTrials.Gov


Prostate Cancer

RTOG 0924

The RTOG 0924 study is for men who have been diagnosed with prostate cancer and have selected to have radiation combined with hormone therapy as their treatment.  This is a multicenter, randomized study trying to determine if giving radiation to the whole pelvis is better at preventing recurrence than giving radiation to the prostate alone.  Men in this study will be randomized to one type of radiation or the other.  This study is not blinded.

Sponsor: NRG Oncology

Principal Investigator: John Stevenson, MD

 Dr Stevenson

Clinical Trials Website: ClinicalTrials.Gov

Astellas TRUMPET Registry

The TRUMPET Registry is available to men who have been diagnosed with metastatic castration-resistant prostate cancer (mCRPC).  These patients must be starting their first or second line of treatment for their metastatic cancer.  This is a registry study which means that it does not specify the type of treatment a patient must receive.  Instead, it gathers information about the types of treatments patients select, the types of side effects they may have and how well their disease responds to the treatments.  The goal of the study is to learn more about the best ways to diagnose, treat and care for patients with this type of cancer.  The TRUMPET Registry asks the men who join to complete questionnaires about their quality of life, symptoms and overall well-being at various time points during the study.

Sponsor: Astellas, Inc.

Principal Investigator: Luko Laptalo, MD

Dr Luke Laptalo MD

 Clinical Trials Website: ClinicalTrials.Gov


Brain Metastases

NRG-CC001

This is a Phase III, randomized, multicenter study for patients diagnosed with metastasis of their cancer to the brain.  Eligible patients will be randomized to receive either whole brain radiation therapy (WBRT) or WBRT with avoidance of an area of the brain known as the hippocampus.  The hippocampus is thought to be important in memory.  The study hopes to determine if avoiding the hippocampus can protect the patient’s cognitive abilities from the effects of the WBRT.  Patient will be randomized to one of the two types of treatment.  This study is not blinded.

Sponsor: NRG Oncology

Principal Investigator: Ellen Wiegner. MD

Dr Weigner

Clinical Trials Website: ClinicalTrials.Gov


Lung Cancer

NILE-Trial

The NILE Trial is for patients who have been recently diagnosed with metastatic non-small cell lung cancer (NSCLC).  NILE uses a type of test called a “blood biopsy” to try to get information about the characteristics of a patient’s cancer.  Currently patients have to have a biopsy to obtain tissue from their cancer to get this information.  This is sometimes difficult and can be painful.  The NILE Trial hopes to show that the results of a simple blood test can be just as good as the results from actual tissue.  There are no specific treatments required in this study.

Sponsor: Guardant Health

Principal Investigator: Sonia Reichert, MD

Dr Reichert

This study is not listed on the ClinicalTrials.gov website

ANPAC

Eligible patients for the ANPAC study will have been diagnosed with Stage I or II non-small cell lung cancer (NSCLC) that will be treated with surgery to remove the cancer.  The ANPAC study uses a new type of blood test called the Cancer Differential Analysis (CDA) to try determine the prognosis for each patient.  Results of the CDA will be compared to CT scans taken approximately 6 months after surgery.

Sponsor: ANPAC Bio, Inc

Principal Investigator: Constanzo DiPerna, MD

Dr DiPerna

This study is not listed on the ClinicalTrials.gov website


Blood Cancer Registries

Miraca

The Miraca Registry is for patients who have been diagnosed with a blood cancer after having a bone marrow biopsy using the Miraca test kit.  The Registry collects information from these patients about their treatments, lab tests, side effects and disease state.  Miraca hopes to learn more about the best ways to diagnose, treat and manage patients with blood cancers.

Sponsor: Miraca Life Sciences

Principal Investigator: Gurvinder Shaheed, MD

Dr Gurvinder

This study is not listed on the ClinicalTrials.gov website

Connect MDS-AML

The Connect MDS-AML Registry is for patients who have been diagnosed with either MDS or AML.  The Registry collects information from these patient about their treatments, lab tests, side effects and disease state.  Connect MDS-AML hopes to learn more about the best ways to diagnose, treat and manage patients who have MDS or AML.

Sponsor: Celgene

Principal Investigator: Shahzad Siddique, MD

Dr Siddique

This study is not listed on the ClinicalTrials.gov website